Patient‐reported outcomes in clinical trials assessing the effectiveness of cabotegravir + rilpivirine long‐acting injections as antiretroviral therapy: A systematic review
HIV Medicine · 2025-09 · 26 (9) · 1343-1355
DOI: 10.1111/hiv.70058 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift HIV Medicine, online erschienen am 02.07.2025. Verfasst von Dhruv Vinay und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Queen's University, Kingston, Ontario, Canada. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, Patient Reported Outcome Measures, Pyridones. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Human immunodeficiency virus‐1 (HIV‐1) continues to have a high global burden, with approximately 39.9 million people currently living with the virus. Despite the clinical success of antiretroviral therapy (ART), adherence remains a significant challenge, often due to emotional distress and HIV‐related stigma. Long‐acting injectables (LAIs) such as the combination of cabotegravir (CAB) and rilpivirine (RPV) have emerged as promising alternatives, reducing the burden of daily pill regimens.
Methods
This systematic review explores the role of CAB + RPV‐LA injectables in antiretroviral therapy (ART), with a focus on patient‐reported outcomes from five key clinical trials.
Results
Findings reveal that CAB + RPV ‐ LA maintains high levels of viral suppression comparable to daily ART while improving patient satisfaction and quality of life. Meta‐analysis of HIV Treatment Satisfaction Questionnaire ( HIVTSQc ) scores across multiple trials demonstrated consistent positive outcomes, with a mean score of 28.83 out of a possible range from −33 to +33, indicating a substantial improvement in patient satisfaction compared to baseline. Qualitative data highlight the psychological and logistical benefits of LAIs , including reduced stigma and enhanced treatment convenience.
Conclusions
This review underscores the potential of CAB + RPV‐LA in improving patient adherence and satisfaction while offering insights for future studies on longer‐term outcomes of LAI use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Queen's University, Kingston, Ontario, Canada.
- Imperial College NHS Trust, London, UK.
- Department of Public Health, Queen's University, Kingston, Ontario, Canada.
ORCID-Profile: Dhruv Vinay, Don Thiwanka D Wijeratne
Zitieren
APA
Vinay, D., Jayaweera, I., Bowman, M., & Wijeratne, D. T. D. (2025). Patient‐reported outcomes in clinical trials assessing the effectiveness of cabotegravir + rilpivirine long‐acting injections as antiretroviral therapy: A systematic review. HIV Medicine, 26(9), 1343-1355. https://doi.org/10.1111/hiv.70058
Vancouver
Vinay D, Jayaweera I, Bowman M, Wijeratne DTD. Patient‐reported outcomes in clinical trials assessing the effectiveness of cabotegravir + rilpivirine long‐acting injections as antiretroviral therapy: A systematic review. HIV Medicine. 2025;26(9):1343-1355. doi:10.1111/hiv.70058
BibTeX
@article{Vinay2025,
author = {Vinay, Dhruv and Jayaweera, Iresh and Bowman, Meghan and Wijeratne, Don Thiwanka D},
title = {Patient‐reported outcomes in clinical trials assessing the effectiveness of cabotegravir + rilpivirine long‐acting injections as antiretroviral therapy: A systematic review},
journal = {HIV Medicine},
year = {2025},
volume = {26},
number = {9},
pages = {1343--1355},
doi = {10.1111/hiv.70058}
}
EUVIMED